Orient Europharma Co Ltd Cash Flow-to-Debt Ratio
Orient Europharma Co Ltd cash flow-to-debt ratio. Orient Europharma Co Ltd (4120) has a Cash Flow-to-Debt Ratio of -0.03x as of September 2025, meaning its operating cash flow of NT$-157.84 Million could theoretically repay 0% of its total liabilities (NT$4.54 Billion) in one year. Check Orient Europharma Co Ltd earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Orient Europharma Co Ltd (2015–2024)
Cash flow-to-debt ratio of Orient Europharma Co Ltd from 2015 to 2024. Historical debt coverage capacity for Orient Europharma Co Ltd across 10 annual periods. Check total reinvestment intensity of Orient Europharma Co Ltd to assess the company's total reinvestment commitment from operating cash flow.
Orient Europharma Co Ltd Cash Flow-to-Debt Ratio by Year (2015–2024)
Orient Europharma Co Ltd cash flow-to-debt ratio by year from 2015 to 2024. Year-by-year debt coverage analysis for Orient Europharma Co Ltd. For the full cash flow conversion analysis, see 4120 cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (TWD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.02x | NT$-121.11 Million | NT$5.75 Billion | ▼ -316.7% |
| 2023 | 0.01x | NT$64.67 Million | NT$6.65 Billion | ▲ +131.1% |
| 2022 | -0.03x | NT$-218.75 Million | NT$6.99 Billion | ▼ -339.9% |
| 2021 | 0.01x | NT$77.65 Million | NT$5.95 Billion | ▼ -90.9% |
| 2020 | 0.14x | NT$608.55 Million | NT$4.25 Billion | ▲ +155.5% |
| 2019 | 0.06x | NT$227.37 Million | NT$4.06 Billion | ▼ -25.0% |
| 2018 | 0.07x | NT$231.31 Million | NT$3.10 Billion | ▼ -68.2% |
| 2017 | 0.24x | NT$601.08 Million | NT$2.56 Billion | ▲ +443.4% |
| 2016 | 0.04x | NT$111.24 Million | NT$2.57 Billion | ▼ -86.0% |
| 2015 | 0.31x | NT$643.97 Million | NT$2.09 Billion | — |